Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
Bio-Path Holdings (NASDAQ: BPTH) announced it will host a conference call and audio webcast on November 15, 2024, at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide a business overview. The company develops DNAbilize®, an RNAi nanoparticle drug technology administered through intravenous transfusion. Their pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. They're also preparing an IND filing for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (NASDAQ: BPTH) ha annunciato che terrà una conference call e una webcast audio il 15 novembre 2024, alle 8:30 ET, per discutere i risultati finanziari del terzo trimestre 2024 e fornire una panoramica aziendale. L'azienda sviluppa DNAbilize®, una tecnologia farmacologica a base di nanoparticelle RNAi somministrata tramite trasfusione endovenosa. Il loro pipeline include prexigebersen (BP1001) in Fase 2 per i tumori del sangue, BP1001-A in Fase 1/1b per tumori solidi e BP1002 che colpisce la proteina Bcl-2 per i tumori ematici e solidi. Stanno anche preparando una domanda IND per BP1003, un inibitore della STAT3.
Bio-Path Holdings (NASDAQ: BPTH) anunció que realizará una llamada de conferencia y un webcast de audio el 15 de noviembre de 2024, a las 8:30 a.m. ET para discutir los resultados financieros del tercer trimestre de 2024 y proporcionar una visión general del negocio. La empresa desarrolla DNAbilize®, una tecnología farmacológica de nanopartículas de RNAi administrada a través de transfusión intravenosa. Su cartera incluye prexigebersen (BP1001) en fase 2 para cánceres de sangre, BP1001-A en fase 1/1b para tumores sólidos y BP1002 que se dirige a la proteína Bcl-2 para cánceres de sangre y tumores sólidos. También están preparando una solicitud de IND para BP1003, un inhibidor de STAT3.
바이오패스 홀딩스 (NASDAQ: BPTH)는 2024년 11월 15일 오전 8시 30분 ET에 2024년 3분기 재무 결과를 논의하고 비즈니스 개요를 제공하기 위한 컨퍼런스 콜 및 오디오 웹캐스트를 개최한다고 발표했습니다. 이 회사는 정맥 주사를 통해 투여되는 RNAi 나노입자 약물 기술인 DNAbilize®를 개발합니다. 그들의 파이프라인에는 혈액암에 대한 2상 시험 중인 prexigebersen (BP1001), 고형 종양에 대한 1상/1b상 시험 중인 BP1001-A, 그리고 혈액암 및 고형 종양을 타겟으로 하는 Bcl-2 단백질을 겨냥한 BP1002가 포함됩니다. 또한 STAT3 억제제인 BP1003에 대한 IND 제출을 준비하고 있습니다.
Bio-Path Holdings (NASDAQ: BPTH) a annoncé qu'elle tiendra une conférence téléphonique et un webinaire audio le 15 novembre 2024, à 8h30 ET, pour discuter des résultats financiers du troisième trimestre 2024 et fournir un aperçu de l'entreprise. La société développe DNAbilize®, une technologie de médicament à base de nanoparticules RNAi administrée par transfusion intraveineuse. Leur pipeline comprend prexigebersen (BP1001) en Phase 2 pour les cancers du sang, BP1001-A en Phase 1/1b pour les tumeurs solides et BP1002 ciblant la protéine Bcl-2 pour les cancers du sang et les tumeurs solides. Ils préparent également un dépôt IND pour BP1003, un inhibiteur de STAT3.
Bio-Path Holdings (NASDAQ: BPTH) gab bekannt, dass am 15. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Audio-Webcast stattfinden werden, um die finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen und einen Überblick über das Unternehmen zu geben. Das Unternehmen entwickelt DNAbilize®, eine RNAi-Nanopartikel-Aroktodie, die durch intravenöse Infusion verabreicht wird. Ihre Pipeline umfasst prexigebersen (BP1001) in Phase 2 für Blutkrebserkrankungen, BP1001-A in Phase 1/1b für solide Tumoren und BP1002, welches auf das Bcl-2 Protein für Blutkrebserkrankungen und solide Tumoren abzielt. Sie bereiten auch eine IND-Anmeldung für BP1003, einen STAT3-Inhibitor, vor.
- Multiple drug candidates in clinical development phases
- Proprietary DNAbilize® technology platform
- Diversified pipeline targeting both blood cancers and solid tumors
- None.
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview.
To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When will Bio-Path Holdings (BPTH) report Q3 2024 earnings?
What clinical trials does Bio-Path Holdings (BPTH) currently have ongoing?
What is Bio-Path Holdings' (BPTH) main technology platform?
